India's Sun Pharmaceutical Industries Ltd. agreed to buy Novartis AG's oncology drug Odomzo for an upfront payment of $175 million plus future milestone payments.
The agreement, which was signed between units of both parties, is subject to antitrust clearance and other closing conditions.
Odomzo, which received FDA approval in July 2015, is used to treat adult patients with locally advanced basal cell carcinoma that recurred after surgery or radiation therapy, or those who are not qualified for surgery or radiation therapy.
Sun Pharma said that the acquisition will support its expansion into branded oncology, adding that the drug has global potential. Odomzo has marketing approval in more than 30 countries.